To delve deeper into the in vivo anti-tumor efficacy of WIP2W and M—WIP2W, WT1+ BP-CML mice received daily treatments of PBS, imatinib, WIP2W, and M—WIP2W for two weeks. Here, WT1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.